カテゴリ： GlobalData, アメリカ, 企業調査

bluebird bio Inc (BLUE)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：bluebird bio Inc (BLUE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9791
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：97
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with various pharmaceutical companies to discover, develop and commercialize gene therapy products to treat cancer. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc (BLUE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
bluebird bio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
bluebird bio Raises US$60 Million In Series D Financing 12
Partnerships 14
bluebird bio and Gritstone Oncology Enter into Agreement 14
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15
Celgene and Bluebird Enter into Co-Development Agreement 16
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17
bluebird bio Amends Co-Development Agreement With Celgene 18
Licensing Agreements 19
bluebird bio Enters into Licensing Agreement with TC BioPharm 19
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20
Novartis Pharma Enters into Licensing Agreement with bluebird bio 21
MediGene Expands Licensing Agreement with bluebird bio 22
Bluebird bio Enters Into Licensing Agreement With ViroMed 23
bluebird bio Enters into Licensing Agreement with National Institutes of Health 24
bluebird bio Enters into Licensing Agreement with Biogen 25
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26
Equity Offering 27
bluebird bio Raises USD632.5 Million in Public Offering of Shares 27
bluebird bio Raises USD651.3 Million in Public Offering of Shares 29
bluebird bio Raises USD460 Million in Public Offering of Shares 31
bluebird bio Raises USD250 Million in Public Offering of Shares 33
Bluebird bio Raises USD500 Million in Public Offering of Shares 35
Bluebird bio Raises USD259 Million in Public Offering of Shares 37
Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39
bluebird bio Completes IPO For US$116 Million 41
Acquisition 43
Bluebird bio Acquires Precision Genome Engineering 43
bluebird bio Inc – Key Competitors 44
bluebird bio Inc – Key Employees 45
bluebird bio Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Nov 01, 2018: bluebird bio reports third quarter 2018 financial results and highlights operational progress 47
Aug 02, 2018: bluebird bio reports second quarter 2018 financial results and highlights operational progress 50
May 02, 2018: bluebird bio Announces First Quarter 2018 Financial Results 53
Feb 21, 2018: bluebird bio Announces Fourth Quarter and Full Year 2017 Financial Results 54
Nov 01, 2017: bluebird bio Reports Third Quarter 2017 Financial Results and Recent Operational Progress 56
Aug 02, 2017: bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress 58
May 03, 2017: bluebird bio Reports First Quarter 2017 Financial Results and Recent Operational Progress 60
Feb 22, 2017: bluebird bio Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Progress 61
Corporate Communications 63
Feb 14, 2018: bluebird bio Names Alison Finger As Chief Commercial Officer 63
Sep 20, 2017: bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors 64
Jun 08, 2017: bluebird bio Appoints John O. Agwunobi, M.D. and Douglas A. Melton, Ph.D. to Board of Directors 65
Product News 66
12/11/2017: bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting 66
10/04/2017: bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine 68
10/04/2017: Gene therapy halts progression of childhood cerebral adrenoleukodystrophy in clinical trial 70
09/06/2017: bluebird bio to Present Interim Clinical Data from Starbeam Study of Lenti-DTM Drug Product in Cerebral Adrenoleukodystrophy at Child Neurology Society 2017 Annual Meeting 72
06/26/2017: bluebird bio Announces Topline Interim Clinical Data from Starbeam Study of Lenti-D Drug Product in Cerebral Adrenoleukodystrophy 73
06/23/2017: bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease at European Hematology Association Annual Meeting 74
06/15/2018: bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia at Annual Congress of the European Hematology Association 76
04/18/2018: bluebird bio Announces New England Journal of Medicine Publication of Interim Data from Two Phase 1/2 Clinical Studies of LentiGlobin Gene Therapy in Patients with Transfusion-Dependent ß-Thalassemia 78
03/01/2017: bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine 80
01/31/2018: Sickle cell gene therapy to boost fetal hemoglobin: A 70-year timeline of discovery 81
Clinical Trials 82
Jun 15, 2018: bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association 82
May 17, 2018: bluebird bio to Present New Data from LentiGlobin Transfusion-Dependent ß-Thalassemia and Severe Sickle Cell Disease Clinical Studies at Annual Congress of the European Hematology Association 84
Dec 10, 2017: bluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia at American Society of Hematology Annual Meeting 86
Nov 16, 2017: bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent ß-Thalassemia (TDT) and ß0/ß0 Genotype 88
Nov 01, 2017: bluebird bio to Present New Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent ß-Thalassemia at ASH Annual Meeting 89
Sep 28, 2017: bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma 92
Jun 23, 2017: bluebird bio Announces Early Data from Phase 3 Northstar-2 (HGB-207) Study of LentiGlobin Drug Product at European Hematology Association (EHA) Annual Meeting 93
May 18, 2017: bluebird bio to Present New Data from LentiGlobin Clinical Studies at European Hematology Association Annual Meeting 94
Feb 03, 2017: bluebird bio Announces First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study of Patients with Severe Sickle Cell Disease 95
Other Significant Developments 96
Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 96
Appendix 97
Methodology 97
About GlobalData 97
Contact Us 97
Disclaimer 97

List of Tables
bluebird bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
bluebird bio Raises US$60 Million In Series D Financing 12
bluebird bio and Gritstone Oncology Enter into Agreement 14
Regeneron Pharma and bluebird bio to Enter into Collaboration Agreement 15
Celgene and Bluebird Enter into Co-Development Agreement 16
Kite Pharma Enters into Co-Development Agreement with Bluebird bio 17
bluebird bio Amends Co-Development Agreement With Celgene 18
bluebird bio Enters into Licensing Agreement with TC BioPharm 19
GlaxoSmithKline Intellectual Property Development Enters into Licensing Agreement with bluebird bio 20
Novartis Pharma Enters into Licensing Agreement with bluebird bio 21
MediGene Expands Licensing Agreement with bluebird bio 22
Bluebird bio Enters Into Licensing Agreement With ViroMed 23
bluebird bio Enters into Licensing Agreement with National Institutes of Health 24
bluebird bio Enters into Licensing Agreement with Biogen 25
Celgene Exercises its Option to Exclusively License bb21217 with bluebird bio 26
bluebird bio Raises USD632.5 Million in Public Offering of Shares 27
bluebird bio Raises USD651.3 Million in Public Offering of Shares 29
bluebird bio Raises USD460 Million in Public Offering of Shares 31
bluebird bio Raises USD250 Million in Public Offering of Shares 33
Bluebird bio Raises USD500 Million in Public Offering of Shares 35
Bluebird bio Raises USD259 Million in Public Offering of Shares 37
Bluebird bio Raises USD117.3 Million in Public Offering of Shares 39
bluebird bio Completes IPO For US$116 Million 41
Bluebird bio Acquires Precision Genome Engineering 43
bluebird bio Inc, Key Competitors 44
bluebird bio Inc, Key Employees 45
bluebird bio Inc, Other Locations 46
bluebird bio Inc, Subsidiaries 46

List of Figures
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[bluebird bio Inc (BLUE)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Global Partners LP：企業の戦略・SWOT・財務情報
    Global Partners LP - Strategy, SWOT and Corporate Finance Report Summary Global Partners LP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • KAZ Minerals PLC：企業の戦略・SWOT・財務情報
    KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report Summary KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • BioView Ltd (BIOV)：医療機器：M&Aディール及び事業提携情報
    Summary BioView Ltd (BioView) develops, manufactures and markets automated cell imaging and analysis solutions, which incorporate proprietary imaging, analysis and review technology. The technology provides automatic control of fully motorized fluorescent and bright-field microscopes fitted with hig …
  • Abbott Diabetes Care Inc：製品パイプライン分析
    Summary Abbott Diabetes Care Inc (ADC), formerly TheraSense Inc, a subsidiary of Abbott Laboratories, is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitor …
  • SQI Diagnostics Inc (SQD)：企業の財務・戦略的SWOT分析
    Summary SQI Diagnostics Inc (SQI Diagnostics) is a diagnostic company that provides in vitro diagnostic and pharmaceutical research products. It provides products such as sqidworks, sqidlite and sqid-X. Its sqidworks system is used in labs. SQI Diagnostic’s sqidlite is a practical benchtop system. I …
  • Nishat Mills Ltd：企業の戦略・SWOT・財務情報
    Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report Summary Nishat Mills Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Lophius Biosciences GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary Lophius Biosciences GmbH (Lophius) is a biotechnology company that develops and markets T cell-based diagnostic systems and research tools in the areas of transplantation, infectious and autoimmune diseases. The company’s T-track immunoscan assay is a test in natural or induced immune modula …
  • Southwestern Energy Co (SWN)：企業の財務・戦略的SWOT分析
    Southwestern Energy Co (SWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Boston Scientific Corp (BSX)：医療機器：M&Aディール及び事業提携情報
    Summary Boston Scientific Corp (Boston Scientific) is a medical device company that develops, manufactures and markets devices used in a range of interventional medical procedures. The company offers products in seven business groups, namely, Interventional Cardiology, Cardiac Rhythm Management (CRM …
  • Dell Technologies Inc (DVMT)：医療機器：M&Aディール及び事業提携情報
    Summary Dell Technologies, Inc. (Dell), is a provider of desktop personal computers, software and peripherals. The company designs, develops, manufactures, markets, sells and supports information technology infrastructure such as laptops, desktops, mobiles, workstations, storage devices and printers …
  • Theravasc Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Theravasc Inc (Theravasc) is a pharmaceutical company that develops treatments for various chronic medical diseases using oral formulation of sodium nitrite. The company’s product includes TV1001SR, a coated oral formulation of sodium nitrite for the treatment of peripheral artery diseases a …
  • AXA Equitable Life Insurance Company：企業の戦略・SWOT・財務分析
    AXA Equitable Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary AXA Equitable Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Honda Motor Co., Ltd.：企業の戦略・SWOT・財務情報
    Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Honda Motor Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Enterprise Products Partners LP (EPD)：石油・ガス：M&Aディール及び事業提携情報
    Summary Enterprise Products Partners LP (Enterprise Products) is a provider of midstream energy services. The company‘s services include natural gas gathering, treating, processing, transportation and storage; transportation of natural gas liquids (NGL), fractionation, storage, and import and export …
  • NIH Office of Technology Transfer-製薬・医療分野：企業M&A・提携分析
    Summary NIH Office of Technology Transfer (NIH OTT), a subsidiary of National Institutes of Health is a healthcare service provider that evaluates, protects, markets, licenses, monitors, and manages NIH and FDA discoveries, inventions, and other intellectual property. The center discovers new biolog …
  • Bio-Rad Laboratories, Inc.：企業の戦略・SWOT・財務分析
    Bio-Rad Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bio-Rad Laboratories, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Parex Resources Inc (PXT)：企業の財務・戦略的SWOT分析
    Summary Parex Resources Inc (Parex) is an oil and gas exploration and development company. The company acquires, explores, develops and produces crude oil and natural gas in South America and the Caribbean. It holds interests in onshore blocks in Magdalena Basins and Colombia's Llanos. Its explorati …
  • Edison International (EIX)-エネルギー分野：企業M&A・提携分析
    Summary Edison International (Edison) is an energy holding company. The company generates and distributes electric power; and invests in energy services and technologies, including renewable power, through its subsidiaries. It develops solar products and carries out commercial rooftop installation o …
  • Datalogic SpA (DAL)：企業の財務・戦略的SWOT分析
    Datalogic SpA (DAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Continuum Wind Energy Ltd-エネルギー分野：企業M&A・提携分析
    Summary Continuum Wind Energy Ltd (Continuum Wind Energy), a subsidiary of Morgan Stanley Infrastructure Partners LP is a renewable energy company that constructs and develops wind farms and wind energy generation. The company's services include optimization of number of wind turbines to maximize ge …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆